DRTSQ1, but make it a science fair
Alpha Tau Medical used its first-quarter 2026 update to do two things at once: show the money and show the medicine. The company reported $80.2 million in cash, cash equivalents, short-term deposits, and restricted deposits, which is the biotech version of saying, “don’t worry, we can keep the lights on while the lab coats keep lab-coating.”
The clinical hits keep coming
The real headline, though, is the trial progress. Alpha Tau said interim U.S. REGAIN data in recurrent glioblastoma showed 100% local disease control and a 67% complete response rate, while the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma finished enrolling patients. Those are the kind of numbers that make investors sit up a little straighter.
Pancreas, pancreas, everywhere
The company also kept stacking pancreatic cancer milestones:
- pooled DDW 2026 data showed 100% local disease control with favorable safety
- the FDA approved an IDE supplement to broaden the IMPACT pancreatic trial to patients on gemcitabine plus Abraxane
- the first patient was treated in Europe under ACAPELLA in France
- the first patient in Italy was treated at the University of Verona
That’s a lot of moving parts, but the message is simple: Alpha Tau is trying to turn Alpha DaRT from a promising concept into a broader clinical platform across multiple tumor types.
Why investors care
The company’s story is still very much “show me the data,” but today’s update gives you both a longer runway and more evidence that the pipeline is advancing. In biotech, that’s often enough to keep the stock interesting — and volatile.
Big picture: Alpha Tau is trying to prove it can be more than a one-trial wonder, and the latest update says the thesis is still alive and kicking.